Publikationen

Publikationen mit Link zu PubMed aus 2018

1. Baumgarten P, Quick-Weller J, Gessler F, Wagner M, Tichy J, Forster MT, Foerch C, Seifert V, Mittelbronn M, Senft C. Pre- and early postoperative GFAP serum levels in glioma and brain metastases. J Neurooncol. 2018 May 24. doi: 10.1007/s11060-018-2898-1. [Epub ahead of print] PubMed PMID: 29797180
2. Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner  JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G,  Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9. PubMed PMID: 29988124.
3. Burger MC, Wagner M, Franz K, Harter PN, Bähr O, Steinbach JP, Senft C. Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases. J Clin Med. 2018 Aug 14;7(8). pii: E216. doi: 10.3390/jcm7080216. PubMed PMID: 30110924.
4. Eriksson JA, Wanka C, Burger MC, Urban H, Hartel I, von Renesse J, Harter PN, Mittelbronn M, Steinbach JP, Rieger J. Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma. J Neurochem. 2018  Feb;144(4):421-430. doi: 10.1111/jnc.14264. Epub 2018 Jan 8. PubMed PMID:29178334.
5. Heller S, Maurer GD, Wanka C, Hofmann U, Luger AL, Bruns I, Steinbach JP, Rieger J. Gene Suppression of Transketolase-Like Protein 1 (TKTL1) Sensitizes Glioma Cells to Hypoxia and Ionizing Radiation. Int J Mol Sci. 2018 Jul 25;19(8). pii: E2168. doi: 10.3390/ijms19082168. PubMed PMID: 30044385.
6. Luger AL, Sauer B, Lorenz NI, Engel AL, Braun Y, Voss M, Harter PN, Steinbach JP, Ronellenfitsch MW. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5). pii: E1504. doi:10.3390/ijms19051504. PubMed PMID: 29772845.
7. Quick-Weller J, Tichy J, Harter PN, Tritt S, Baumgarten P, Bähr O, Dinc N, Behmanesh B, Weise L, Seifert V, Marquardt G. "Two is not enough" - Impact of the number of tissue samples obtained from stereotactic brain biopsies in suspected glioblastoma. J Clin Neurosci. 2018 Jan;47:311-314. doi: 10.1016/j.jocn.2017.09.032. Epub 2017 Oct 24. PubMed PMID: 29078974.
8. Ronellenfitsch MW, Oh JE, Satomi K, Sumi K, Harter PN, Steinbach JP, Felsberg J, Capper D, Voegele C, Durand G, McKay J, Le Calvez-Kelm F, Schittenhelm J, Klink B, Mittelbronn M, Ohgaki H. CASP9 germline mutation in a family with multiple brain tumors. Brain Pathol. 2018 Jan;28(1):94-102. doi: 10.1111/bpa.12471. Epub 2017 Apr 17. PubMed PMID: 27935156.
9. Ronellenfitsch MW, Zeiner PS, Mittelbronn M, Urban H, Pietsch T, Reuter D, Senft C, Steinbach JP, Westphal M, Harter PN. Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. Acta Neuropathol Commun. 2018 Aug 21;6(1):81. doi: 10.1186/s40478-018-0583-4. PubMed PMID: 30129426. 
10. Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock  A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. Tumor  growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. J Cancer Res Clin Oncol. 2018 May 28. doi: 10.1007/s00432-018-2671-z. [Epub ahead of print] PubMed PMID: 29808316.
11. Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed,
    MGMT-nonmethylated glioblastoma. Neuro Oncol. 2018 Jun 18;20(7):975-985. doi:10.1093/neuonc/nox204. PubMed PMID: 29121274
12. Voss M, Lorenz NI, Luger AL, Steinbach JP, Rieger J, Ronellenfitsch MW. Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet. Int J Mol Sci. 2018 Aug20;19(8). pii: E2462. doi: 10.3390/ijms19082462. PubMed PMID: 30127309. 
13. Zeiner PS, Zinke J, Kowalewski DJ, Bernatz S, Tichy J, Ronellenfitsch MW, Thorsen F, Berger A, Forster MT, Muller A, Steinbach JP, Beschorner R, Wischhusen J, Kvasnicka HM, Plate KH, Stefanović S, Weide B, Mittelbronn M, Harter PN. CD74  regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival. Acta Neuropathol Commun. 2018 Mar 1;6(1):18. doi: 10.1186/s40478-018-0521-5. PubMed PMID: 29490700; PubMed Central PMCID: PMC5831742.

Publikationen mit Link zu PubMed aus 2017

1. Antonietti P, Linder B, Hehlgans S, Mildenberger IC, Burger MC, Fulda S, Steinbach JP, Gessler F, Rödel F, Mittelbronn M, Kögel D. Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic-Induced Apoptosis. Mol Cancer Ther. 2017 Jan ;16(1):156-168. Epub 2016 Oct 24. PubMed PMID: 27777286.
2. Bauer S, van Alphen N, Becker A, Chiocchetti A, Deichmann R, Deller T, Freiman T, Freitag CM, Gehrig J, Hermsen AM, Jedlicka P, Kell C, Klein KM, Knake S, Kullmann DM, Liebner S, Norwood BA, Omigie D, Plate K, Reif A, Reif PS, Reiss Y, Roeper J, Ronellenfitsch MW, Schorge S, Schratt G, Schwarzacher SW, Steinbach JP, Strzelczyk A, Triesch J, Wagner M, Walker MC, von Wegner F, Rosenow F. Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches. Epilepsy Behav. 2017 Nov;76:7-12. Epub 2017 Sep 14. Review. PubMed PMID: 28917498.
3. Blasel S, Alex S, Ackermann H, Tichy J, Berkefeld J, Wagner M. Low-Dose CCT to Exclude Contraindications to Lumbar Puncture : Benefits and Limitations. Clin Neuroradiol. 2017 Sep 30. doi: 10.1007/s00062-017-0628-2. [Epub ahead of print] PubMed PMID: 28965126.
4. Burger MC, Breuer S, Cieplik HC, Harter PN, Franz K, Bähr O, Steinbach JP. Bevacizumab for Patients with Recurrent Multifocal Glioblastomas. Int J Mol Sci. 2017 Nov 20;18(11). pii: E2469 PubMed PMID: 29156610.
5. Burger MC, Mildenberger IC, Wagner M, Mittelbronn M, Steinbach JP, Bähr O. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern. Int J Mol Sci. 2017 Mar 29;18(4). pii: E726. PubMed PMID: 28353668; PubMed Central PMCID: PMC5412312.
6. Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, Langen KJ, Brandts C, Senft C, Harter PN, Bähr O. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncol Rep. 2017 Dec;38(6):3291-3296. Epub 2017 Oct 2. PubMed PMID: 29039591.
7. Bähr O, Gross S, Harter PN, Kirches E, Mawrin C, Steinbach JP, Mittelbronn M. ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. Oncol Lett. 2017 Nov;14(5):5443-5451. Epub 2017 Aug 28. PubMed PMID: 29098034; PubMed Central PMCID: PMC5652230.
8. Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Estrem ST, Lahn MM, Wick W. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combinationof Galunisertib and Lomustine. Int J Mol Sci. 2017 May 6;18(5). pii: E995. PubMed PMID: 28481241; PubMed Central PMCID: PMC5454908.
9. Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017 Jun;57:36-49. Epub 2017 May 18. Review. PubMed PMID: 28550712.
10. Ilina EI, Armento A, Sanchez LG, Reichlmeir M, Braun Y, Penski C, Capper D, Sahm F, Jennewein L, Harter PN, Zukunft S, Fleming I, Schulte D, Le Guerroué F, Behrends C, Ronellenfitsch MW, Naumann U, Mittelbronn M. Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux. Oncotarget. 2017 Jun 27;8(40):67567-67591. eCollection 2017 Sep 15. PubMed PMID: 28978054; PubMed Central PMCID: PMC5620194.
11. Knöchel C, Voss M, Gruter F, Alves GS, Matura S, Sepanski B, Stablein M, Kraft D, Prvulovic D, Carvalho AF, Reif A, Oertel-Knochel V. Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia. Curr Alzheimer Res. 2017;14(3):240-254. doi: 10.2174/1567205013666160602235520. Review. PubMed PMID: 27335040.
12. Quick-Weller J, Tritt S, Baumgarten P, Konczalla J, Kashefiolasl S, Noack A, Tichy J, Seifert V, Marquardt G. Positive influence of partial resection on overall survival of patients with overlapping glioblastomas. Clin Neurol Neurosurg. 2017 Oct;161:22-28. Epub 2017 Jun 29. PubMed PMID: 28837843.
13. Quick-Weller J, Tichy J, Dinc N, Tritt S, Won SY, Behmanesh B, Bruder M, Seifert V, Weise LM, Marquardt G. Benefit and Complications of Frame-Based Stereotactic Biopsy in Old and Very Old Patients. World Neurosurg. 2017 Jun;102:442-448. Epub 2017 Mar 23. PubMed PMID: 28344180.
14. Rosenow F, van Alphen N, Becker A, Chiocchetti A, Deichmann R, Deller T, Freiman T, Freitag CM, Gehrig J, Hermsen AM, Jedlicka P, Kell C, Klein KM, Knake S, Kullmann DM, Liebner S, Norwood BA, Omigie D, Plate K, Reif A, Reif PS, Reiss Y, Roeper J, Ronellenfitsch MW, Schorge S, Schratt G, Schwarzacher SW, Steinbach JP, Strzelczyk A, Triesch J, Wagner M, Walker MC, von Wegner F, Bauer S. Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches. Epilepsy Behav. 2017 Nov;76:13-18. Epub 2017 Sep 13. Review. PubMed PMID: 28917501.
15. Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M, Gaida B, von Podewils F, Rosenow F. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals. Epilepsy Behav. 2017 May;70(Pt A):177-181. Epub 2017 Apr 17. PubMed PMID: 28427029.
16. Thiepold AL, Lorenz NI, Foltyn M, Engel AL, Divé I, Urban H, Heller S, Bruns I, Hofmann U, Dröse S, Harter PN, Mittelbronn M, Steinbach JP, Ronellenfitsch MW. Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death. Brain. 2017 Oct 1;140(10):2623-2638. PubMed PMID: 28969371.
17. Vietheer JM, Rieger J, Wagner M, Senft C, Tichy J, Foerch C. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma. J Neurooncol. 2017 Oct;135(1):193-199. Epub 2017 Jul 17. PubMed PMID: 28717884.
18. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L,  Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): arandomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. PubMed PMID: 28844499.
19. Wenger KJ, Hattingen E, Franz K, Steinbach J, Bähr O, Pilatus U. In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas. Clin Neuroradiol. 2017 Oct 5. PubMed PMID: 28983683.
20. Wenger KJ, Hattingen E, Franz K, Steinbach JP, Bähr O, Pilatus U. Intracellular pH measured by (31) P-MR-spectroscopy might predict site of progression in recurrent glioblastoma under antiangiogenic therapy. J Magn Reson Imaging. 2017 Oct;46(4):1200-1208. Epub 2017 Feb 6. PubMed PMID: 28165649.
21. Wenger KJ, Wagner M, You SJ, Franz K, Harter PN, Burger MC, Voss M, Ronellenfitsch MW, Fokas E, Steinbach JP, Bähr O. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol Lett. 2017 Jul;14(1):1141-1146. doi: 10.3892/ol.2017.6251. Epub  2017 May 25. PubMed PMID: 28693286; PubMed Central PMCID: PMC5494648.

Publikationen mit Link zu PubMed aus 2016

1. Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bähr O, Mäder L, Goeppert B, Machein M, Seifert V, Steinbach JP, Plate KH, Harter PN, Mittelbronn M. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol. 2016 Feb;18(2):173-83
2. Baumgarten P, Gessler F, Schittenhelm J, Skardelly M, Tews DS, Senft C, Dunst M, Imoehl L, Plate KH, Wagner M, Steinbach JP, Seifert V, Mittelbronn M, Harter PN. Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. Acta Neuropathol. 2016 Sep;132(3):479-81
3. Blasel S, Zagorcic A, Jurcoane A, Bähr O, Wagner M, Harter PN, Hattingen E.  Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence. J Neuroimaging. 2016 Jan-Feb;26(1):116-23
4. Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn MM, Wick W. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 2016 Aug;18(8):1146-56
5. Brucker DP, Maurer GD, Harter PN, Rieger J, Steinbach JP. FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death.  Int J Oncol. 2016 Dec;49(6):2399-2410
6. Burger MC, Zeiner PS, Jahnke K, Wagner M, Mittelbronn M, Steinbach JP. Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors. PLoS One. 2016 Jun 2;11(6):e0155315
7. Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, Bähr O, Trojan J. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. J Gastrointest Cancer. 2016 Mar;47(1):82-8
8. Genßler S, Burger MC, Zhang C, Oelsner S, Mildenberger I, Wagner M, Steinbach  JP, Wels WS. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 2015 Dec 21;5(4)
9. Hartel I, Ronellenfitsch M, Wanka C, Wolking S, Steinbach JP, Rieger J. Activation of AMP-activated kinase modulates sensitivity of glioma cells against epidermal growth factor receptor inhibition. Int J Oncol. 2016 Jul;49(1):173-80
10. Herrlinger U, Jones DT, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol. 2016 Feb;131(2):309-19
11. Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol. 2016 May 10;34(14):1611-9
12. Jennewein L, Ronellenfitsch MW, Antonietti P, Ilina EI, Jung J, Stadel D, Flohr LM, Zinke J, von Renesse J, Drott U, Baumgarten P, Braczynski AK, Penski C, Burger MC, Theurillat JP, Steinbach JP, Plate KH, Dikic I, Fulda S, Brandts C, Kögel D, Behrends C, Harter PN, Mittelbronn M. Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas. Oncotarget. 2016 Apr 12;7(15):20016-32
13. Knöchel C, Voss M, Grüter F, Alves GS, Matura S, Sepanski B, Stäblein M, Kraft D, Prvulovic D, Carvalho AF, Reif A, Oertel-Knöchel V. Omega-3 fatty acids: repurposing opportunities for cognition and biobehavioral disturbances in MCI and Dementia. Curr Alzheimer Res. 2016 Jun 2. [Epub ahead of print]
14. Kortland LM, Alfter A, Bähr O, Carl B, Dodel R, Freiman TM, Hubert K, Jahnke K, Knake S, von Podewils F, Reese JP, Runge U, Senft C, Steinmetz H, Rosenow F, Strzelczyk A. Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany. Epilepsia. 2016 Dec;57(12):2056-2066
15. Rieger J, Steinbach JP. To diet or not to diet - that is still the question. Neuro Oncol. 2016 Aug;18(8):1035-6
16. Ronellenfitsch MW, Ji Eun O, Satomi K, Sumi K, Harter PN, Steinbach JP, Felsberg J, Capper D, Voegele C, Durand G, McKay J, Le Calvez-Kelm F, Schittenhelm J, Klink B, Mittelbronn M, Ohgaki H. CASP9 Germline Mutation in a Family with Multiple Brain Tumors. Brain Pathol. 2016 Dec 9
17. Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2016 Aug;129(1):93-100
18. Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach JP, Trojan J, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH, Reiss Y. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med. 2015 Dec 14;8(1):39-57
19. Steidl E, Pilatus U, Hattingen E, Steinbach JP, Zanella F, Ronellenfitsch MW, Bähr O. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. PLoS One. 2016 Dec 29; 11(12):e0168113
20. Tichy J, Spechtmeyer S, Mittelbronn M, Hattingen E, Rieger J, Senft C, Foerch C. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J Neurooncol. 2016 Jan;126(2):361-9
21. Zhang C*, Burger MC*, Jennewein L, Genßler S, Schönfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. *Shared First Author. J Natl Cancer Inst. 2015 Dec 6;108(5)
    
    

Publikationen mit Link zu PubMed aus 2015

1. Blasel S, Zagorcic A, Jurcoane A, Bähr O, Wagner M, Harter PN, Hattingen E. Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence. J Neuroimaging. 2016 Jan-Feb;26(1):116-23. doi: 10.1111/jon.12247. Epub 2015 Apr 24. 
2. Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, Mittelbronn M,  Bähr O, Weyerbrock A, Stuhr L, Miletic H, Sakariassen PØ, Stieber D, Rygh CB, Lund-Johansen M, Zheng L, Gottlieb E, Niclou SP, Bjerkvig R. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol. 2015 Jan;129(1):115-31. doi: 10.1007/s00401-014-1352-5.
3. Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
   Oncotarget. 2015 Dec 1;6(38):40836-49. doi: 10.18632/oncotarget.5696.
   
4. Harter PN, Jennewein L, Baumgarten P, Ilina E, Burger MC, Thiepold AL, Tichy J, Zörnig M, Senft C, Steinbach JP, Mittelbronn M, Ronellenfitsch MW. Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors. PLoS One. 2015 May 19;10(5):e0127123. doi: 10.1371/journal.pone.0127123.
5. Lescher S, Jurcoane A, Veit A, Bähr O, Deichmann R, Hattingen E. Quantitative  T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI. Neuroradiology. 2015 Jan;57(1):11-20. doi: 10.1007/s00234-014-1445-9.
6. Meyer-Ohlendorf M, Braczynski A, Al-Qaisi O, Gessler F, Biskup S, Weise L, Steinbach JP, Wagner M, Mittelbronn M, Bähr O. Comprehensive diagnostics in a case of hereditary diffuse leukodystrophy with spheroids. BMC Neurol. 2015 Jul 4;15:103. doi: 10.1186/s12883-015-0368-3.
   
7. Nöth U, Hattingen E, Bähr O, Tichy J, Deichmann R. Improved visibility of brain tumors in synthetic MP-RAGE anatomies with pure T1 weighting. NMR Biomed. 2015 Jul;28(7):818-30. doi: 10.1002/nbm.3324.
8. Thiepold AL, Luger S, Wagner M, Filmann N, Ronellenfitsch MW, Harter PN, Braczynski AK, Dützmann S, Hattingen E, Steinbach JP, Senft C, Rieger J, Bähr O.  Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma.  Oncotarget. 2015 Jun 10;6(16):14537-44.
   
9. Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah  G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737.
   
10. Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0.
11. Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz  D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015 Mar;51(4):522-32. doi: 10.1016/j.ejca.2014.12.019.
12. Tichy J, Zinke J, Bunz B, Meyermann R, Harter PN, Mittelbronn M. Expression Profile of Sonic Hedgehog Pathway Members in the Developing Human Fetal Brain. Biomed Res Int. 2015;2015:494269. doi: 10.1155/2015/494269.

Publikation mit Link zu PubMed aus 2014

1. Baumgarten P, Michaelis M, Rothweiler F, Starzetz T, Rabenau HF, Berger A, Jennewein L, Braczynski AK, Franz K, Seifert V, Steinbach JP, Allwinn R, Mittelbronn M, Cinatl J Jr. Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics. Neuro Oncol. 2014 Nov;16(11):1469-77. doi: 10.1093/neuonc/nou167. Epub 2014 Aug 25. PubMed PMID: 25155358; PubMed Central PMCID: PMC4201076.
2. Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch  T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M, Wick W.  NDRG1 prognosticates the natural course of disease in WHO grade II glioma. J Neurooncol. 2014 Mar;117(1):25-32. doi: 10.1007/s11060-013-1357-2. Epub 2014 Jan  7. PubMed PMID: 24395351.
3. Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger  J, Steinbach JP, Hattingen E. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology. 2014 Jul 15;83(3):227-34. doi: 10.1212/WNL.0000000000000594. Epub 2014 Jun 13. Erratum in: Neurology. 2014 Sep 16;83(12):1123. PubMed PMID: 24928118.
4. Fischer S, Ronellenfitsch MW, Thiepold AL, Harter PN, Reichert S, Kögel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, Fulda S, Bähr O. Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. PLoS One. 2014 Apr 17;9(4):e94921. doi: 10.1371/journal.pone.0094921. eCollection 2014. PubMed PMID: 24743710; PubMed Central PMCID: PMC3990545.
5. Harter PN, Zinke J, Scholz A, Tichy J, Zachskorn C, Kvasnicka HM, Goeppert B,  Delloye-Bourgeois C, Hattingen E, Senft C, Steinbach JP, Plate KH, Mehlen P, Schulte D, Mittelbronn M. Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases. PLoS One. 2014 Mar 19;9(3):e92311. doi: 10.1371/journal.pone.0092311. eCollection 2014. PubMed PMID: 24647424; PubMed Central PMCID: PMC3960244.
6. Lescher S, Jurcoane A, Veit A, Bähr O, Deichmann R, Hattingen E. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI. Neuroradiology. 2015 Jan;57(1):11-20. doi: 10.1007/s00234-014-1445-9. Epub 2014 Oct 7. PubMed PMID: 25287076.
7. Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M; German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer. 2014 Oct 15;135(8):1822-31. doi: 10.1002/ijc.28836. Epub 2014 Mar 28. PubMed PMID: 24615357.
8. Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014 Jun;44(6):1843-52. doi: 10.3892/ijo.2014.2382. Epub 2014 Apr 11. Erratum in: Int J Oncol. 2014 Dec;45(6):2605. PubMed PMID: 24728273; PubMed Central PMCID: PMC4063533.
9. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19. PubMed PMID: 25163906.
10. Thiepold AL, Lemercier S, Franz K, Atta J, Sulzbacher A, Steinbach JP, Rieger J. Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma. Pharmacotherapy. 2014 Jun;34(6):633-42. doi: 10.1002/phar.1409. Epub 2014 Mar 11. PubMed PMID: 24619825.
11. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G,  Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, Hielscher T, Rübmann P, Pfenning PN, Ronellenfitsch M, Kempf T, Schnölzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):409-14. doi: 10.1073/pnas.1314469111. Epub 2013 Dec 23. PubMed PMID: 24367102; PubMed Central PMCID: PMC3890826.
12. Weise LM, Harter PN, Eibach S, Braczynski AK, Dunst M, Rieger J, Bähr O, Hattingen E, Steinbach JP, Plate KH, Seifert V, Mittelbronn M. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies. Stereotact Funct Neurosurg. 2014;92(3):129-39. doi: 10.1159/000360582. Epub 2014 Apr 24. PubMed PMID: 24776650.

Publikationen mit Link zu PubMed aus 2013

1. Blasel S, Jurcoane A, Bähr O, Weise L, Harter PN, Hattingen E. MR perfusion in and around the contrast-enhancement of primary CNS lymphomas. J Neurooncol. 2013  Aug;114(1):127-34. doi: 10.1007/s11060-013-1161-z. Epub 2013 May 22. PubMed PMID: 23695516.
2. Fokas E, Steinbach JP, Rödel C. Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta. 2013 Jan;1835(1):61-75. doi: 10.1016/j.bbcan.2012.10.005. Epub 2012 Nov 7. Review. PubMed PMID: 23142311.
3. Hattingen E, Jurcoane A, Daneshvar K, Pilatus U, Mittelbronn M, Steinbach JP, Bähr O. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Neuro Oncol. 2013 Oct;15(10):1395-404. doi: 10.1093/neuonc/not105. Epub 2013 Aug 7. PubMed PMID: 23925453; PubMed Central PMCID: PMC3779046.
4. Hattingen E, Bähr O, Rieger J, Blasel S, Steinbach J, Pilatus U. Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy. PLoS One. 2013;8(3):e56439. doi: 10.1371/journal.pone.0056439. Epub 2013 Mar 8. PubMed PMID: 23520454; PubMed Central PMCID: PMC3592858.
5. Platten M, Steinbach JP, Wick W. [Personalized neurooncology]. Nervenarzt. 2013 Aug;84(8):937-42. doi: 10.1007/s00115-013-3758-z. Review. German. PubMed PMID: 23775285.
6. Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M. Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain. 2013 Feb;136(Pt 2):564-76. doi: 10.1093/brain/aws351. Epub 2013 Jan 31. PubMed PMID: 23378223.
7. Weiler M, Pfenning PN, Thiepold AL, Blaes J, Jestaedt L, Gronych J, Dittmann LM, Berger B, Jugold M, Kosch M, Combs SE, von Deimling A, Weller M, Bendszus M,  Platten M, Wick W. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene. 2013 Feb 28;32(9):1099-109. doi: 10.1038/onc.2012.137. Epub 2012 May 7. PubMed PMID: 22562250.
8. Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, von Deimling A, Shei P, Moreau-Donnet V, Stoffregen C, Combs SE. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro Oncol. 2013 Oct;15(10):1405-12. doi: 10.1093/neuonc/not100. Epub 2013 Aug 1. PubMed PMID: 23911595; PubMed Central PMCID: PMC3779043.
9. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W; Neuro-oncology Working Group (NOA) of the German Cancer Society. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 2013 Aug;15(8):1017-26. doi: 10.1093/neuonc/not043. Epub 2013 Apr 17. PubMed PMID: 23595628; PubMed Central PMCID: PMC3714152.

Supplement

1. Steinbach J, Vordermark D, Gutzmer R. [CNS metastases--an interdisciplinary challenge]. Onkologie. 2013;36 Suppl 4:2-6. doi: 10.1159/000350920. Epub 2013 May 7. German. PubMed PMID: 23797363.
   
   

Publikationen mit Link zu PubMed aus 2012

1. Burger MC, Brucker DP, Baumgarten P, Ronellenfitsch MW, Wanka C, Hasselblatt M, Eccles MR, Klingebiel T, Weller M, Rieger J, Mittelbronn M, Steinbach JP. PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. Int  J Oncol. 2012 Jul;41(1):235-41. doi: 10.3892/ijo.2012.1446. Epub 2012 Apr 25. PubMed PMID: 22552444.
2. Bähr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Körtvelyessy P, Franz K, Tatagiba M, Seifert V, Weller M, Steinbach JP. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir (Wien). 2012 Feb;154(2):229-35; discussion 235. doi: 10.1007/s00701-011-1144-9. Epub 2011 Sep  10. PubMed PMID: 21909835.
3. Fokas E, Steinbach JP, Rödel C. Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta. 2013 Jan;1835(1):61-75. doi: 10.1016/j.bbcan.2012.10.005. Epub 2012 Nov 7. Review. PubMed PMID: 23142311.
4. Thiepold AL, Lemercier S, Franz K, Atta J, Sulzbacher A, Steinbach JP, Rieger  J. Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma. Pharmacotherapy. 2014 Jun;34(6):633-42. doi: 10.1002/phar.1409. Epub 2014 Mar 11. PubMed PMID: 24619825.
5. Wanka C, Steinbach JP, Rieger J. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem.  2012 Sep 28;287(40):33436-46. Epub 2012 Aug 10. PubMed PMID: 22887998; PubMed Central PMCID: PMC3460445.
6. Wanka C, Brucker DP, Bähr O, Ronellenfitsch M, Weller M, Steinbach JP, Rieger  J. Synthesis of cytochrome C oxidase 2: a p53-dependent metabolic regulator that  promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene. 2012 Aug 16;31(33):3764-76. doi: 10.1038/onc.2011.530. Epub 2011 Nov 28. PubMed PMID: 22120717.
7. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. PubMed PMID: 28844499.
8. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J,  Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012 Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10. PubMed PMID: 22578793.

Publikationen mit Link zu PubMed aus 2011

1. Bähr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Körtvelyessy P, Franz K, Tatagiba M, Seifert V, Weller M, Steinbach JP. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir (Wien). 2012 Feb;154(2):229-35; discussion 235. doi: 10.1007/s00701-011-1144-9. Epub 2011 Sep  10. PubMed PMID: 21909835.
2. Bähr O, Hattingen E, Rieger J, Steinbach JP. Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol. 2011 Sep;13(9):1020-9. doi: 10.1093/neuonc/nor099. Epub 2011 Jul 31. PubMed PMID: 21807668; PubMed Central PMCID: PMC3158018.
3. Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. Strahlenther Onkol. 2011 Nov;187(11):722-8. doi: 10.1007/s00066-011-2230-x. Epub  2011 Oct 28. PubMed PMID: 22037649.
4. Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub 2011 Jun 27. PubMed PMID: 21710625.
5. Hattingen E, Jurcoane A, Bähr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U. Bevacizumab impairs oxidative energy metabolism and shows antitumoral  effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol. 2011 Dec;13(12):1349-63. doi: 10.1093/neuonc/nor132. Epub 2011 Sep 2. PubMed PMID: 21890539; PubMed Central PMCID: PMC3223092.
6. Karnath HO, Steinbach JP. Do brain tumours allow valid conclusions on the localisation of human brain functions?--Objections. Cortex. 2011 Sep;47(8):1004-6. doi: 10.1016/j.cortex.2010.08.006. Epub 2010 Sep 9. PubMed PMID: 20869700.
7. Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP, Rieger J. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011 Jul 26;11:315. doi: 10.1186/1471-2407-11-315. PubMed PMID: 21791085; PubMed Central PMCID: PMC3199865.
8. Schäfer N, Tichy J, Thanendrarajan S, Kim Y, Stuplich M, Mack F, Rieger J, Simon M, Scheffler B, Boström J, Steinbach JP, Herrlinger U, Glas M. Ifosfamide,  carboplatin and etoposide in recurrent malignant glioma. Oncology. 2011;80(5-6):330-2. doi: 10.1159/000330358. Epub 2011 Jul 27. PubMed PMID: 21791942.
9. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim  CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19. PubMed PMID: 25163906. 
10. Wagner M, Nafe R, Jurcoane A, Pilatus U, Franz K, Rieger J, Steinbach JP, Hattingen E. Heterogeneity in malignant gliomas: a magnetic resonance analysis of spatial distribution of metabolite changes and regional blood volume. J Neurooncol. 2011 Jul;103(3):663-72. doi: 10.1007/s11060-010-0443-y. PubMed PMID: 21061143.
11. Wanka C, Brucker DP, Bähr O, Ronellenfitsch M, Weller M, Steinbach JP, Rieger J. Synthesis of cytochrome C oxidase 2: a p53-dependent metabolic regulator that  promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene. 2012 Aug 16;31(33):3764-76. doi: 10.1038/onc.2011.530. Epub 2011 Nov 28. PubMed PMID: 22120717.